Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Brand Names
Ixiaro
Generic Name
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)
DrugBank Accession Number
DB10769
Background

Not Available

Type
Biotech
Groups
Approved
Biologic Classification
Vaccines
Inactivated
Synonyms
  • Japanese encephalitis vaccine
  • Japanese encephalitis vaccine IC51
  • Japanese encephalitis virus (inactivated)
  • Japanese encephalitis virus strain SA 14-14-2 antigen (formaldehyde inactivated)
External IDs
  • IC-51
  • IC51

Pharmacology

Indication

Not Available

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbataceptThe therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Abatacept.
AdalimumabThe therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Adalimumab.
AldesleukinThe therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Aldesleukin.
AlefaceptThe therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Alefacept.
AlemtuzumabThe therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Alemtuzumab.
AltretamineThe therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Altretamine.
AmsacrineThe therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Amsacrine.
AnakinraThe therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Anakinra.
Antilymphocyte immunoglobulin (horse)The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Antilymphocyte immunoglobulin (horse).
Antithymocyte immunoglobulin (rabbit)The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
No interactions found.

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
IxiaroInjection, suspension6 ug/0.5mLIntramuscularValneva Scotland Ltd.2009-03-30Not applicableUS flag
IxiaroSuspension6 mcg / 0.5 mLIntramuscularValneva Austria Gmbh2009-12-29Not applicableCanada flag
IxiaroInjection, suspension6 ug/0.5mLIntramuscularVetter Pharma Fertigung GmbH & Co. KG2009-03-30Not applicableUS flag
IxiaroInjection, suspension6 AUIntramuscularValneva Austria Gmb H2020-12-23Not applicableEU flag
IxiaroInjection, suspension6 [arb'U]/0.5mLIntramuscularValneva Scotland Ltd.2009-03-30Not applicableUS flag
IxiaroInjection, suspension6 AUIntramuscularValneva Austria Gmb H2020-12-23Not applicableEU flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
DZ854I04ZE
CAS number
Not Available

References

General References
Not Available
RxNav
1300779
AHFS Codes
  • 80:12.00 — Vaccines

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedBasic ScienceEncephalitis, Japanese B / Japanese Encephalitis Vaccine1
4CompletedBasic ScienceHumoral and Cellular Immune Responses1
4CompletedPreventionEncephalitis, Japanese B2
4CompletedPreventionEncephalitis, Japanese B / Mumps / Rubella / Rubeola1
4CompletedPreventionInflammation, Brain1
4Enrolling by InvitationPreventionEncephalitis, Japanese B / Vaccine Preventable Disease / Vaccine Reaction1
4RecruitingPreventionJapanese Encephalitis Vaccine1
4Unknown StatusPreventionHand, Foot and Mouth Disease (HFMD)1
3Active Not RecruitingPreventionJapanese Encephalitis Virus Disease1
3CompletedOtherEncephalitis, Japanese B1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, solution1 ml
Injection, suspensionIntramuscular6 AU
Injection, suspensionIntramuscular6 [arb'U]/0.5mL
Injection, suspensionIntramuscular6 ug/0.5mL
Injection, suspensionIntramuscular; Subcutaneous
SuspensionIntramuscular6 mcg / 0.5 mL
InjectionSubcutaneous
Injection, powder, lyophilized, for solution0.5 ml
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on December 01, 2015 20:04 / Updated on June 12, 2021 01:53